Blood Coagulation Factor VIII Measurement Using Waveform Differentiation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for measuring blood coagulation activity in patients administered with Lonoctocog alfa are complex and prone to human error, particularly when converting measured values using the one-step coagulation method.

Innovation Solution

A method that involves acquiring parameters related to the differentiation of coagulation waveforms in blood specimens to accurately measure blood coagulation factor VIII activity, using a polypeptide with a specific sequence or high identity, thereby simplifying the measurement process and reducing human error.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If the one-step coagulation method is used to measure Lonoctocog alfa activity, then the measurement process is simplified, but the measurement accuracy deteriorates due to the need for conversion factor multiplication

Engineering Contradiction:
Improvemeasurement process simplicityVSAvoidactivity measurement accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The invention changes the measurement parameter from requiring conversion factor multiplication to directly using the measured value. By establishing a calibration curve with Lonoctocog alfa standards and using the area under the curve (AUC) as the measurement parameter, the method eliminates the need for post-measurement conversion, thereby maintaining operational simplicity while improving measurement accuracy.

Inventive Principle:
Principle #35Parameter changes

2Measurement precision

If conversion factor multiplication is applied to all specimens, then measurement accuracy for Lonoctocog alfa patients is improved, but process complexity and human error risk increase

Engineering Contradiction:
Improveactivity measurement accuracyVSAvoidmeasurement process complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The invention extracts and removes the conversion factor multiplication step from the measurement process. By using Lonoctocog alfa standards in the calibration curve, the method directly measures activity without requiring subsequent conversion, thereby eliminating the complex step that increases process complexity and human error risk while maintaining measurement accuracy.

Inventive Principle:
Principle #2Taking out (Extraction)

3Adaptability or versatility

If conventional one-step coagulation method with conversion factors is used, then measurement coverage is broad, but human error increases due to identification and multiplication steps

Engineering Contradiction:
Improvespecimen measurement coverageVSAvoidmeasurement reliability
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The invention enables the measurement system to automatically differentiate and accurately measure Lonoctocog alfa specimens without requiring manual identification or conversion. The calibration curve with Lonoctocog alfa standards allows the system to self-adjust and provide accurate measurements directly, eliminating manual intervention steps that reduce reliability while maintaining broad specimen coverage.

Inventive Principle:
Principle #25Self-service

Data Source

PatentEP3889613A1Method for measuring a blood coagulation activity
Publication Date: 2021.10.06 SYSMEX CORP
  • EP3889613A1 patent drawingFigure 1A~1B
  • EP3889613A1 patent drawingFigure 2A~2C
  • EP3889613A1 patent drawingFigure 3A

AI summary

Disclosed is a method for measuring a blood coagulation activity, comprising: acquiring a parameter related to differentiation of a coagulation waveform in a blood specimen collected from a patient administered with (1) a polypeptide containing a sequence represented by SEQ ID NO: 1, or (2) a polypeptide containing a polypeptide having 95% or more identity with the sequence represented by SEQ ID NO: 1 and having an activity as a blood coagulation factor VIII; and acquiring an activity value of a blood coagulation factor VIII in the blood specimen based on the acquired parameter.